Combination treatment with telitacicept,mycophenolate mofetil and glucocorticoids for immunoglobulin A nephropathy:A case report  

作　　者：Yan Shen Jin Yuan Shuang Chen Yong-Feng Zhang Ling Yin Qin Hong Yan Zha 

机构地区：[1]Department of Nephrology,Guizhou Provincial People's Hospital,Guiyang 550002,Guizhou Province,China

出　　处：《World Journal of Clinical Cases》2024年第29期6307-6313,共7页世界临床病例杂志

摘　　要：BACKGROUND Telitacicept reduces B cell activation and abnormal immunoglobulin A(IgA)antibody production by inhibiting the activity of B lymphocyte stimulator(BLyS)and a proliferation-inducing ligand(APRIL),thereby decreasing IgA deposition in the glomeruli and local inflammatory response.This ultimately protects the kidneys from damage.This mechanism suggests that Telitacicept has potential efficacy in the treatment of IgA nephropathy.CASE SUMMARY We present the case of a 24-year-old female who was diagnosed with IgA nephropathy due to significant proteinuria and mild renal impairment.Pathologically,she exhibited focal proliferative glomerulonephritis.Treatment with angiotensin II receptor blocker,hormones,and mycophenolate mofetil did not lead to a significant improvement in her condition.However,upon the addition of telitacicept,the patient’s renal function recovered and her proteinuria rapidly reduced.Hormones were swiftly tapered and discontinued,with no occurrence of severe infections or related complications.CONCLUSION Telitacicept combined with hormones and mycophenolate mofetil may be a safe and effective induction therapy for IgA nephropathy.

关 键 词：IgA nephropathy Telitacicept Mycophenolate mofetil GLUCOCORTICOIDS Case report 

分 类 号：R692[医药卫生—泌尿科学]